Health & Fitness
Thu, August 30, 2012
SAN MARINO, Calif.--([ BUSINESS WIRE ])--Viral Genetics (Pinksheets: VRAL) published its August 2012 Letter to Shareholders which is available on the company website at:
[ http://www.viralgenetics.com/shareholder-letters/Letter-to-Shareholders-Aug-12.PDF ].
In the letter, the companyas president, Mr. Haig Keledjian, offers insight into the companyas ongoing progress in several key areas:
- Our VG Energy subsidiary continues development of biofuel and agricultural products with the potential to radically decrease the cost of plant oils and bio-diesel fuels;
- Phase 1 clinical trial for drug-resistant ovarian cancer has enrolled its first patients and has commenced;
- We are in the process of scheduling a pre-IND meeting with the FDA regarding establishing a clinical trial for a new potential drug for chronic Lyme Disease;
- Our potential drug for HIV/AIDS that does not rely on antiviral activity is nearing clinical trials;
- We currently have in progress, a pipeline of 5-10 additional drug candidates for Multiple Sclerosis, PANDAS, Sepsis, Staph and Strep infection, among other diseases.
Additional details on these programs is available by [ clicking this link. ]
About Viral Genetics, Inc.
San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy ([ www.vgenergy.net ]), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit [ www.viralgenetics.com ].
About VG Energy
VG Energy Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc., a biotechnology company researching new treatments and methods of detection for diseases including cancer, HIV/AIDS and others. Using its Metabolic Disruption Technology (MDT), Viral Geneticsa cancer research led to discoveries with major consequences in a wide variety of other industries, including biofuel, vegetable oils and other high value oils and chemicals. VG Energy holds the exclusive worldwide license to the MDT patent rights for use in the increase of production of various plant-derived oils from algae and seeds. These pivotal discoveries promise to allow the biofuel industry to overcome its major obstacle in the area of production efficiency: namely, an increase in production yields leading to feasible economic returns on investment, allowing renewable biodiesel to be competitive with fossil fuels. For more information, please visit [ http://www.vgenergy.net ].
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.as non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.
